[Prevention of infection and improvement of cenesthesia with thymostimulin during chemotherapy following mastectomy].
Eighty-five breast cancer patients who had been operated for mastectomy and were currently undergoing adjuvant or therapeutic chemotherapy were included in the study. Patients were divided into two matching groups of 50 (A) and 35 (B) subjects; group A was treated with CT and thymostimulin Serono and group B with CT alone. The difference between the two groups in relation to first-degree (24% vs 57%) and second-degree leucopenia (8% vs 14%), in addition to the difference in relation to infections and the regularity of chemotherapy cycles confirmed the value of immunotherapy with thymostimulin during chemotherapy for breast cancer.
Alba
E
E
Istituto di Ginecologia ed Ostetricia, Università degli Studi di Torino.
Visentin
L
L
Farina
C
C
Wierdis
T
T
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000601:surgery*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008408:Mastectomy; D011183:Postoperative Complications / Q000517:prevention & control*; D013530:Surgical Wound Infection / Q000517:prevention & control; D013949:Thymus Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D013949:Thymus Extracts; C031407:thymostimulin
Prevenzione dei processi infettivi e miglioramento della cenestesi con timostimolina in pazienti mastectomizzate in corso di chemioterapia.